secwatch.observer — SEC 8-K summary
======================================

Issuer:     LABCORP HOLDINGS INC. (LH)
CIK:        0000920148
Form:       8-K
Filed at:   2025-04-29T23:59:59+00:00
Accession:  0000920148-25-000054
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Labcorp Q1 revenue $3.35B (+5.3% YoY), adj. EPS $3.84 vs $3.68; raises midpoint of FY adj. EPS guidance
--------------------------------------------------------------------------------

- Revenue $3.35B, GAAP diluted EPS $2.52 (down from $2.69), adjusted EPS $3.84 (up from $3.68).
- Raised adjusted EPS guidance midpoint to $15.70–$16.40; revenue and free cash flow guidance reaffirmed.
- Diagnostics segment revenue $2.63B (+6.0%), adjusted operating margin 16.3% (down 60bps due to Invitae and weather).
- Biopharma segment revenue $721.3M (+1.5%), adjusted operating margin 14.8% (up 80bps).
- Announced acquisitions of BioReference Health oncology assets and Inspira Health lab management; new liquid biopsy test Labcorp Plasma Complete.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/920148/000092014825000054/0000920148-25-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/920148/000092014825000054/lh-20250429.htm
  HTML page:      https://secwatch.observer/filing/0000920148-25-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer